Table 2. Off-Label Direct Oral Anticoagulant Dosing.
| Total n (%) | Higher-than-recommended Dosing n (%) | Lower-than-recommended Dosing n (%) | Other* n (%) | |
|---|---|---|---|---|
| All DOACs | 40 (16.1) | 7 (17.5) | 28 (70.0) | 5 (12.5) |
| Dabigatran | 4 | 0 | 4 (10) | 0 |
| Rivaroxaban | 19 | 5 (26.3) | 12 (63.2) | 2 (10.5) |
| Apixaban | 17 | 2 (11.8) | 12 (70.6) | 3 (17.6) |
*
Reasons dosing classification was prevented in these patients included concomitant St. John’s wort (n=1) and phenytoin (n=1) which are contraindicated with apixaban; and Child-Pugh B or C hepatic impairment where no dosing guidance is provided (n=3).
DOAC: direct oral anticoagulant